Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2022 11:52 ET | Source: Dyve Biosciences

Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress

CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
June 01, 2022 08:00 ET | Source: Dyve Biosciences

Dyve Biosciences to Participate in the BIO International Convention

CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
May 04, 2022 08:30 ET | Source: Dyve Biosciences

Dyve Biosciences to Present at the UBS Global Healthcare Conference

CAMARILLO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
March 09, 2022 08:00 ET | Source: Dyve Biosciences

Dyve Biosciences to Present at the 34th Annual Roth Conference

CAMARILLO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline...
March 01, 2022 07:00 ET | Source: Dyve Biosciences

Dyve Biosciences Announces the Appointment of Nicholas A. Saccomano, Ph.D., to its Scientific Advisory Board

- Former Array BioPharma and Pfizer Executive Joins Dyve Biosciences - CAMARILLO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company...
February 22, 2022 08:00 ET | Source: Dyve Biosciences

Dyve Biosciences to Present at the Biocom California Global Life Science Partnering Conference

CAMARILLO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
February 16, 2022 08:00 ET | Source: Dyve Biosciences

Dyve Biosciences to Present at the 32nd Annual Oppenheimer Healthcare Conference

CAMARILLO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
February 03, 2022 08:00 ET | Source: Dyve Biosciences

Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center

CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a...
November 15, 2021 08:00 ET | Source: Dyve Biosciences

Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702

Two key opinion leaders will discuss gout treatment landscape and perspectives on Phase 2 TARGETS study of DYV702 for the treatment of pain associated with acute gout flares Webinar to be...
February 01, 2021 08:00 ET | Source: Dyve Biosciences

Dyve Biosciences Appoints Camilla V. Simpson to Board of Directors

THOUSAND OAKS, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that Camilla V. Simpson has joined Dyve’s Board of...